Andrew Jacob Silver, Chief Financial Officer of CRISPR Therapeutics AG, filed a Form 4 on October 28, 2026, reporting the grant of stock options and restricted stock units on October 26, 2026.

Key Highlights

  • Stock option grant: Silver received a stock option to purchase 18,000 Common Shares at an exercise price of $49.01, granted on October 26, 2026, with an expiration date of October 26, 2036.
  • RSU grant: Silver also received 9,000 restricted stock units on October 26, 2026, each representing a contingent right to receive one CRISPR Therapeutics Common Share.
  • Option vesting schedule: According to the filing, 100% of the 18,000 option shares vest in 48 equal monthly installments, with the first vesting date of November 26, 2026.
  • RSU vesting schedule: The 9,000 RSUs vest in four equal annual installments of 25% each, on October 26, 2027, October 26, 2028, October 26, 2029, and October 26, 2030.
  • Price of derivative securities: Both the stock option and RSU awards were reported at a price of $0 at acquisition.
  • Reporting person role: Silver is identified in the filing as Chief Financial Officer of CRISPR Therapeutics AG, trading on NASDAQ:CRSP.

CFO Silver's October 2026 Equity Award Details

According to the Form 4 filed with the U.S. Securities and Exchange Commission, Andrew Jacob Silver, Chief Financial Officer of CRISPR Therapeutics AG (NASDAQ:CRSP), received two equity awards on October 26, 2026. The first is a stock option granting the right to purchase 18,000 Common Shares at an exercise price of $49.01 per share. The option carries an expiration date of October 26, 2036, and vests in 48 equal monthly installments, with the first vesting date of November 26, 2026, as stated in the filing.

The second award consists of 9,000 restricted stock units, each representing a contingent right to receive one CRISPR Therapeutics Common Share, according to the filing. The RSUs vest in four equal annual tranches of 25% each, on October 26, 2027; October 26, 2028; October 26, 2029; and October 26, 2030. Both awards are held directly by Silver and were acquired under transaction code "A," indicating an acquisition. The filing reports the price of both derivative securities at acquisition as $0.

The Form 4 was signed by Elizabeth Ryland Waldinger as attorney-in-fact on October 28, 2026. No non-derivative securities transactions were reported in Table I of the filing. Following the reported transactions, Silver beneficially owns 18,000 stock options and 9,000 restricted stock units directly, as disclosed in the filing.

What Was Disclosed

The filing disclosed that CRISPR Therapeutics CFO Andrew Jacob Silver received a stock option for 18,000 Common Shares at $49.01 and an RSU award for 9,000 Common Shares, both granted on October 26, 2026, with distinct multi-year vesting schedules.